Semaglutide Improves Severe Liver Disease in Phase 3 Trial
Semaglutide effectively treated the life-threatening liver disease metabolic dysfunction–associated steatohepatitis (MASH) in nearly 2 out of 3 patients, or 63%, a phase 3 clinical trial found.
Significant Weight Loss With CagriSema, But Less Than Hoped
Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes improve their health. Medscape Medical News
STAT+: GLP-1 drug helped type 1 diabetes patients keep healthy glucose levels and lose weight
Obesity drugs were first approved to treat type 2 diabetes, but there’s a growing movement to test them in type 1 diabetes, too. Research presented Monday at a large diabetes meeting showed some promise for this approach. Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood […]
Experimental drug helps patients lose nearly a quarter of body weight in early trials
An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. The drug, amycretin — developed by Novo Nordisk — works by replicating two hunger hormones — amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that […]
Weekly semaglutide improves blood sugar and weight in adults with type 1 diabetes, clinical trial finds
A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with type 1 diabetes who use automated insulin delivery systems.
Ozempic Shows Benefit in Type 1 Diabetes Patients With Obesity
(MedPage Today) — CHICAGO — Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed.
In this 26-week, double-blind trial of 72 adults, 36% who received 1 mg of the…
Dual-target weight loss drug controls blood sugar and appetite but causes gastrointestinal side effects in early trials
A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which targets both GLP-1 and amylin receptors to help control blood sugar and appetite, was reported to reduce body weight by up to 24.3% when injected over 36 weeks, and 13.1% when taken orally over […]
Diabetes-Related Healthcare Costs Have Plateaued, Marking a Rare Opportunity for Employers, Nomi Health Report Finds
Image Credit: Nomi Health What You Should Know: – After decades of relentless increases, diabetes-related healthcare costs have finally plateaued, according to a new analysis by Nomi Health. The key finding from the company’s latest “Trends in Spend” report marks a rare moment of opportunity for self-funded employers to re-evaluate how they manage one of […]
GLP-1 Patients Missed Over $10M in Potential Savings in a Single Quarter, Report Finds
What You Should Know: – A new data analysis from DoseSpot, a leader in e-prescribing and healthcare technology solutions, found that 92 percent of GLP-1 prescriptions the company processed in Q1 2025 could have been filled at a lower price. This translates to a staggering $10.2M in missed savings for patients on these popular medications. […]
BrightGene tops Novo drug in diabetes ahead of Zepbound showdown
BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. The biotech linked its challenger to bigger reductions in blood sugar than Novo Nordisk’s semaglutide, giving momentum as it barrels toward a readout from a head-to-head trial against Eli Lilly’s tirzepatide.